相关实验视频
Updated: Jul 14, 2026

05:41
Non-invasive Assessment of Microvascular and Endothelial Function
Published on: January 29, 2013
在患有充血性心力衰竭的患者中,四肢血管对β-上腺素受体刺激的反应
M A Creager1, R J Quigg, C J Ren
1Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 02115.
Circulation
|June 1, 1991
概括
在患有充血性心力衰竭的患者中,β-上腺素受体脱敏不会导致肢体血管扩张受损. 在心力衰竭患者中,四肢血流对异二醇和酸的反应得到了保留.
科学领域:
- 心血管生理学心血管生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 充血性心力衰竭 (CHF) 与降低对β-上腺激动剂的反应有关.
- 周围β-上腺受体脱敏作用在CHF中肢体血管扩张受损的作用尚不清楚.
研究的目的:
- 调查β-腺素受体脱敏化是否有助于CHF患者的肢体血管扩张异常.
主要方法:
- 给13名心血管衰竭患者和14名健康对照者注射异二醇 (β-激动剂) 和酸 (血管扩张剂) 的脑内动脉输液.
- 测量了前臂血液流动,使用静脉封闭囊造影.
- 在反应性高血压期间评估了最大的血管扩张潜力.
主要成果:
- 对异二醇的最大前臂血流反应在CHF患者和对照组中是相似的.
- 在CHF患者中,异二醇和酸的剂量反应关系保持不变.
- 在CHF患者中血上升的上腺素水平与异二醇反应无关.
结论:
- 在患有充血性心力衰竭的患者中,β-腺素受体脱敏并不是肢体血管扩张受损的原因.
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Peripheral Artery Disease IV: Nursing Management
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...

